Transport of Estrone 3-sulfate Mediated by Organic Anion Transporter OATP4C1: Estrone 3-sulfate binds to the Different Recognition Site for Digoxin in OATP4C1

doi:10.2133/dmpk.25.314

Drug Metabolism and Pharmacokinetics

Volume 25, Issue 3, 2010, Pages 314-317

https://doi.org/10.2133/dmpk.25.314 Get rights and content

Summary:

Human organic anion transporter OATP4C1 is a member of the OATP family predominantly expressed in the kidney, and contributes to the renal secretion of digoxin. However, little is known about the characteristics of OATP4C1-madiated transport. We examined the transport of estrone 3-sulfate, which is known as a substrate for other OATPs, by OATP4C1-expressing cells. Estrone 3-sulfate was efficiently transported by OATP4C1. The Michaelis-Menten constant for estrone 3-sulfate uptake by OATP4C1 was 26.6 ± 4.9 μM. Transport of estrone 3-sulfate was significantly inhibited by triiodothyronine, chenodeoxycholic acid, bromosulfophtalein, and cyclosporine, whereas known substrates of OATP4C1, digoxin and ouabain, did not change OATP4C1-mediated transport. We further examined the mutual inhibition study between estrone 3-sulfate and digoxin. Digoxin partially inhibited the estrone 3-sulfate transport, and estrone 3-sulfate did not significantly inhibit digoxin transport. The estimated IC₅₀ value of digoxin for OATP4C1-mediated estrone 3-sulfate transport was 119 μM. This value is not comparable with the Michaelis-Menten constant for digoxin uptake by OATP4C1 (7.8 μM) reported by Mikkaichi et al.¹⁾ In conclusion, we found that estrone 3-sulfate is a novel substrate for OATP4C1. Moreover, our results indicate that estrone 3-sulfate does not bind to the recognition site for digoxin in OATP4C1.

References (11)

B. Hagenbuch et al.
The superfamily of organic anion transporting polypeptides
Biochim. Biophys. Acta
(2003)
G.A. Kullak-Ublick et al.
Enterohepatic bile salt transporters in normal physiology and liver disease
Gastroenterology
(2004)
T. Mikkaichi et al.
The organic anion transporter (OATP) family
Drug Metab. Pharmacokinet.
(2004)
X. Bossuyt et al.
Multispecfic amphipathic substrate transport by an organic anion transporter of human liver
J. Hepatol.
(1996)
Y. Cui et al.
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6
J. Biol. Chem.
(2001)

There are more references available in the full text version of this article.

Cited by (46)

Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency
2020, Clinical Therapeutics
This study aimed to utilize a population pharmacokinetic method to obtain information about the influence of covariates on the in vivo behavior of digoxin in patients with cardiac insufficiency.
A total of 228 therapeutic drug monitoring concentrations were retrospectively collected from 176 inpatients. The patients were randomly divided into a modeling group (n = 126) and a validation group (n = 50). The first-order absorption one-compartment model was used to develop a population pharmacokinetic model from a nonlinear mixed effects modeling approach. Sixteen single nucleotide polymorphisms involved in the pharmacokinetic variables of digoxin were identified by using the MassARRAY system. Various demographic parameters, biochemical test values, concomitant medications, and genetic variants were investigated.
The typical population value of digoxin CL/F was 5.06 L/h, and the volume of distribution was 211.82 L. The drug CL/F was significantly related to serum creatinine, in a combination of spironolactone and SLCO4C1 genotypes of 2 variants (rs3114660 and rs3114661). Results of model evaluation and internal/external validation indicated a stable and precise performance of the final model.
For the first time, 2 single nucleotide polymorphisms (rs3114660 and rs3114661) in SLCO4C1 were found to significantly affect the elimination of digoxin in vivo. The final population model may be useful for the individualized dosing of digoxin for patients with cardiac insufficiency.
Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside
2020, Pharmacology and Therapeutics
Organic solute transporter alpha/beta (OSTα/β) is a heteromeric solute carrier protein that transports bile acids, steroid metabolites and drugs into and out of cells. OSTα/β protein is expressed in various tissues, but its expression is highest in the gastrointestinal tract where it facilitates the recirculation of bile acids from the gut to the liver. Previous studies established that OSTα/β is upregulated in liver tissue of patients with extrahepatic cholestasis, obstructive cholestasis, and primary biliary cholangitis (PBC), conditions that are characterized by elevated bile acid concentrations in the liver and/or systemic circulation. The discovery that OSTα/β is highly upregulated in the liver of patients with nonalcoholic steatohepatitis (NASH) further highlights the clinical relevance of this transporter because the incidence of NASH is increasing at an alarming rate with the obesity epidemic. Since OSTα/β is closely linked to the homeostasis of bile acids, and tightly regulated by the nuclear receptor farnesoid X receptor, OSTα/β is a potential drug target for treatment of cholestatic liver disease, and other bile acid-related metabolic disorders such as obesity and diabetes. Obeticholic acid, a semi-synthetic bile acid used to treat PBC, under review for the treatment of NASH, and in development for the treatment of other metabolic disorders, induces OSTα/β. Some drugs associated with hepatotoxicity inhibit OSTα/β, suggesting a possible role for OSTα/β in drug-induced liver injury (DILI). Furthermore, clinical cases of homozygous genetic defects in both OSTα/β subunits resulting in diarrhea and features of cholestasis have been reported. This review article has been compiled to comprehensively summarize the recent data emerging on OSTα/β, recapitulating the available literature on the structure-function and expression-function relationships of OSTα/β, the regulation of this important transporter, the interaction of drugs and other compounds with OSTα/β, and the comparison of OSTα/β with other solute carrier transporters as well as adenosine triphosphate-binding cassette transporters. Findings from basic to more clinically focused research efforts are described and discussed.
Dysregulation of renal transporters in a rodent model of viral Infection
2020, International Immunopharmacology
Inflammation elicited by viral mimetic poly I:C has been shown to impose changes in the expression of drug transporters in the placenta and maternal liver in rats at term pregnancy. This was associated with altered drug disposition in the mother and fetus. Renal transporters play an important role in the elimination of several drugs taken by pregnant women. We examined the impact of poly I:C on the expression of renal transporters in pregnant rats at term. Pregnant Sprague-Dawley rats received single intraperitoneal dose of either poly I:C (5 mg/kg) or saline at gestation day 18 (n = 8/group). Animals were euthanized 24 h after the injection. The mRNA and protein expression of pro-inflammatory cytokines and transporters were measured by qRT-PCR and western blot. Poly I:C caused a fourfold increase in the mRNA of IL-6 in the kidney. As compared to saline controls, the mRNA expression of Mrp2, Bcrp, Octn1, Oat1, Oat2, Oat3, Urat1, Oatp4c1, and Pept2 was downregulated, whereas the Ent1 mRNA was increased. Protein expression of Bcrp, Urat1 and Pept2 were significantly decreased. While there was a trend towards reduced Mrp2, Oat2 and Oat3 protein expression, this did not reach significance. Poly I:C did not impact mRNA levels of Mdr1a, Mdr1b, Mrp4, Oct1, Oct2, Oct3, Octn2, Mate1, Ent2 or Pept1. Viral-induced inflammation mediates significant changes in the expression of several key drug transporters in the kidney of pregnant rats. Many clinically important drugs are substrates for these transporters. Therefore, inflammation-mediated alterations in transporter expression could affect their maternal and fetal disposition.
Xenobiotic Transporters in the Kidney: Function and Role in Toxicity
2019, Seminars in Nephrology
Summary:The kidney plays a critical role in the elimination of many xenobiotics, and drug-induced kidney injury is a risk factor in drug discovery and development. In addition, accumulation of nephrotoxic compounds, a process often controlled by xenobiotic transporters, is often a prerequisite to kidney injury. Such adverse events are dependent on many transporters, particularly those in the solute carrier and adenosine triphosphate–binding cassette superfamilies. This review details the current understanding of how kidney transporters contribute to toxic outcomes and highlights critical knowledge gaps regarding species differences that account for some lack of predictivity between preclinical animal models and human beings. The basic classification, physiological roles, and species differences of solute carrier and adenosine triphosphate–binding cassette transporters is reviewed, along with mechanistic details for drug-induced kidney injury involving transporters. The use of preclinical data (in vitro and in vivo), clinical data, and conventional as well as emerging tools for studying kidney transporter function are summarized. Finally, we highlight some challenges and opportunities to improve experimental approaches to support preclinical and clinical studies of kidney transporters and their role in nephrotoxicity.
Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine
2019, Pharmacology and Therapeutics
Intestinal transporter proteins, along with drug metabolizing enzymes, play a major role in the disposition of orally administered drugs, nutrients and xenobiotics. In this regard, efflux transporters such as ABCB1 and ABCG2 can limit oral bioavailability, while uptake carriers such as PEPT1 have the potential to facilitate intestinal absorption. In contrast to the extensive information on intestinal efflux pumps, detailed knowledge about the respective uptake carriers is rather limited. During the last decade, organic anion transporting polypeptide (OATP) transporters have been frequently discussed as clinically relevant uptake transporters for endogenous compounds as well as drugs. Many drug-drug interactions or food-drug interactions that have been observed have been attributed to inhibition of intestinal OATPs. Moreover, an OATP-mediated drug delivery approach assumes OATPs to be target for improving oral drug absorption. However, recent data from several research groups question the established paradigm of intestinal OATPs as uptake carriers. This review aims to provide a comprehensive up-to-date overview regarding the expression, localization and function of OATP transporters in the human intestine.
Kidney-on-a-Chip: Technologies for Studying Pharmacological and Therapeutic Approaches to Kidney Repair
2017, Kidney Transplantation, Bioengineering, and Regeneration: Kidney Transplantation in the Regenerative Medicine Era
Chronic kidney disease (CKD) is a global health problem with significant morbidity and mortality. Currently, the only two therapeutic options offered to patients are dialysis and renal transplantation, but each with significant limitations. There is a critical need for improved model systems to study renal tissue repair or predict drug efficacy and safety. Recent advances in tissue culture systems acknowledge the importance of the tissue microenvironment in optimal functioning and responsiveness. Communication between cells is essential as well as biomechanic and chemotactic processes, which influence cell proliferation, migration, and differentiation processes. These processes are advanced when tissues are cultured in 3D-platforms and under continuous flow conditions. This chapter gives an overview of innovative technologies related to 3D kidney cell cultures. Examples of three technologies (hollow fiber membranes, gel-based systems, and microfluidics) will be discussed with respect to their suitability in studying pharmacological and therapeutic approaches in regenerative nephrology.

View all citing articles on Scopus

: This work was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

View full text

Short CommunicationTransport of Estrone 3-sulfate Mediated by Organic Anion Transporter OATP4C1: Estrone 3-sulfate binds to the Different Recognition Site for Digoxin in OATP4C1

Summary:

Biochim. Biophys. Acta

Gastroenterology

Drug Metab. Pharmacokinet.

J. Hepatol.

J. Biol. Chem.

Short Communication
Transport of Estrone 3-sulfate Mediated by Organic Anion Transporter OATP4C1: Estrone 3-sulfate binds to the Different Recognition Site for Digoxin in OATP4C1